Tags

Type your tag names separated by a space and hit enter

A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Ann Hematol 2016; 95(3):417-23AH

Abstract

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma characterized by a unique clinical and histological presentation. Because of the rare nature of this disease, few large-scale studies are available. We conducted a cohort study in which patients were identified in the Netherlands Cancer Registry in the Southeast of the Netherlands between 1990 and 2010. Of these patients, we collected all clinical characteristics and re-reviewed pathologic material to confirm NLPHL diagnosis. Seventy-three histologically confirmed cases of NLPHL were analyzed with a median follow-up of 65 months (range 4-257 months). Median age at diagnosis was 43 years (range 1-87); 84.9 % of the patients were male; B symptoms were present in 5.5 %; and stage I/II disease was most common (75.4 %). Patients were primarily treated with radiotherapy (50.7 %), chemotherapy (26 %), combined modality (radiotherapy and chemotherapy) (11 %), or surgical excision with careful watch-and-wait (12.3 %). Relapses occurred in seven patients (9.6 %) after a median of 26 months (21-74 months). Six patients (8.2 %) developed histologic transformation to large cell lymphoma. Five patients (6.8 %) died during follow-up due to progression of NLPHL (n = 1), histologic transformation (n = 2) and intercurrent deaths (n = 2). The estimated 10-year overall survival was 94.0 % and the 10-year progression-free survival 75.8 %. Our study confirms the distinct characteristics of NLPHL with a relatively good long-term prognosis. It may be possible to reduce treatment intensity in early stage NLPHL without affecting long-term outcome.

Authors+Show Affiliations

Department of Hematology, Radboud University Medical Center, Geert Grooteplein 8, 6525 GA Nijmegen, Postbus 9101, 6500 HB, Nijmegen, The Netherlands. l.strobbe@gelre.nl.Department of Hematology, Radboud University Medical Center, Geert Grooteplein 8, 6525 GA Nijmegen, Postbus 9101, 6500 HB, Nijmegen, The Netherlands.Department of Hematology, Radboud University Medical Center, Geert Grooteplein 8, 6525 GA Nijmegen, Postbus 9101, 6500 HB, Nijmegen, The Netherlands.Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.Department of Registry and Research, Comprehensive Cancer Center, Utrecht, The Netherlands.Department of Hematology, Radboud University Medical Center, Geert Grooteplein 8, 6525 GA Nijmegen, Postbus 9101, 6500 HB, Nijmegen, The Netherlands. Department of Hematology, Rijnstate Hospital, Arnhem, The Netherlands.Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26732883

Citation

Strobbe, L, et al. "A 20-year Population-based Study On the Epidemiology, Clinical Features, Treatment, and Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma." Annals of Hematology, vol. 95, no. 3, 2016, pp. 417-23.
Strobbe L, Valke LL, Diets IJ, et al. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. Ann Hematol. 2016;95(3):417-23.
Strobbe, L., Valke, L. L., Diets, I. J., van den Brand, M., Aben, K., Raemaekers, J. M., ... van Krieken, J. H. (2016). A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. Annals of Hematology, 95(3), pp. 417-23. doi:10.1007/s00277-015-2578-6.
Strobbe L, et al. A 20-year Population-based Study On the Epidemiology, Clinical Features, Treatment, and Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma. Ann Hematol. 2016;95(3):417-23. PubMed PMID: 26732883.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. AU - Strobbe,L, AU - Valke,L L F G, AU - Diets,I J, AU - van den Brand,M, AU - Aben,K, AU - Raemaekers,J M M, AU - Hebeda,K M, AU - van Krieken,J H J M, Y1 - 2016/01/05/ PY - 2015/05/25/received PY - 2015/12/09/accepted PY - 2016/1/7/entrez PY - 2016/1/7/pubmed PY - 2016/6/23/medline KW - Chemotherapy KW - Epidemiology KW - Nodular lymphocyte predominant Hodgkin lymphoma KW - Outcome KW - Radiotherapy SP - 417 EP - 23 JF - Annals of hematology JO - Ann. Hematol. VL - 95 IS - 3 N2 - Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma characterized by a unique clinical and histological presentation. Because of the rare nature of this disease, few large-scale studies are available. We conducted a cohort study in which patients were identified in the Netherlands Cancer Registry in the Southeast of the Netherlands between 1990 and 2010. Of these patients, we collected all clinical characteristics and re-reviewed pathologic material to confirm NLPHL diagnosis. Seventy-three histologically confirmed cases of NLPHL were analyzed with a median follow-up of 65 months (range 4-257 months). Median age at diagnosis was 43 years (range 1-87); 84.9 % of the patients were male; B symptoms were present in 5.5 %; and stage I/II disease was most common (75.4 %). Patients were primarily treated with radiotherapy (50.7 %), chemotherapy (26 %), combined modality (radiotherapy and chemotherapy) (11 %), or surgical excision with careful watch-and-wait (12.3 %). Relapses occurred in seven patients (9.6 %) after a median of 26 months (21-74 months). Six patients (8.2 %) developed histologic transformation to large cell lymphoma. Five patients (6.8 %) died during follow-up due to progression of NLPHL (n = 1), histologic transformation (n = 2) and intercurrent deaths (n = 2). The estimated 10-year overall survival was 94.0 % and the 10-year progression-free survival 75.8 %. Our study confirms the distinct characteristics of NLPHL with a relatively good long-term prognosis. It may be possible to reduce treatment intensity in early stage NLPHL without affecting long-term outcome. SN - 1432-0584 UR - https://www.unboundmedicine.com/medline/citation/26732883/A_20_year_population_based_study_on_the_epidemiology_clinical_features_treatment_and_outcome_of_nodular_lymphocyte_predominant_Hodgkin_lymphoma_ L2 - https://dx.doi.org/10.1007/s00277-015-2578-6 DB - PRIME DP - Unbound Medicine ER -